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Abstract
Hepatitis C virus (HCV) is a cause of liver diseases that range from steatohepatitis, to fibrosis,
cirrhosis, and hepatocellular carcinoma (HCC). The challenge of understanding the pathogenesis
of HCV-associated liver cancer is difficult as most standard animal models used in biomedical
research are not permissive to HCV infection. Herein, we provide an overview of a number of
creative in vivo, mostly in the mouse, and in vitro models that have been developed to advance our
understanding of the molecular and cellular effects of HCV on the liver, specifically with their
relevance to HCC.
1. Introduction
A recent re-analysis of the worldwide global burden of cancer [1] places liver as the 5th most
prevalent target organ in terms of the estimated new cases in man, and 7th in women. Most
importantly, liver cancer is one of the most deadly cancers, as it is the 2nd leading cause of
cancer death in man and 6th in women worldwide. An estimated 748,000 new liver cancer
cases and 696,000 cancer deaths occurred worldwide in 2008 with the highest liver cancer
rates are reported in East and South-East Asia, and in Middle and Western Africa. Among
primary liver cancers, hepatocellular carcinoma (HCC) represents the major subtype,
accounting for 70% to 85% of the total liver cancer burden worldwide.
Among many potential etiological factors that have been causally linked to human cancers,
including HCC, infectious agents represent an important sub-group of agents that have been
classified as “carcinogenic to humans” by the International Agency for Research on Cancer
Monographs Program [2]. Liver is a major cancer site associated with four Group 1
infectious agents: hepatitis B and C viruses, O. viverrini and C. sinensis. With regards to
hepatitis C virus (HCV), the relative risk estimate for developing liver cancer in patients
with serologically-confirmed HCV infection is estimated to be 17, as compared to 2.5 for
HCV-associated non-Hodgkin lymphomas [3]. Importantly, the age-adjusted incidence of
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HCC is increasing in many countries, including the United States [4], and has been widely
attributed to the spread of HCV infection in many industrialized countries [5].
About 2%-3% of the world's population is living with HCV infection, with country-specific
prevalence rates ranging from <1% to over 10% [6]. Each year, it is estimated that over
350,000 people die worldwide of HCV-related diseases, predominantly liver cirrhosis and
liver cancer [6]. In the United States alone, HCV and associated diseases carry a very high
economic burden and it was estimated in 2012 that there are over 50 new drugs in
development to treat hepatitis C [7; 8]. Given the societal, economic and other pressures, the
field of HCV studies is very vibrant and spans the spectrum of investigations in infectious
disease and virology from mechanistic and clinical research, to drug development and
epidemiology. However, relatively few studies have focused on the mechanisms underlying
the association of liver cancer with HCV, and it is still largely unresolved whether the virus
is directly carcinogenic (e.g. causes mutations, genomic instability, or transformation of
liver cells), or whether other pathological conditions in the liver (steatosis, inflammation,
oxidative stress, and fibrogenesis) that are associated with the chronic viral infection are to
blame [5].
Since the discovery of HCV in 1989 [9], our knowledge has expanded exponentially and a
plethora of model systems is being utilized by researchers who are interested in HCV itself,
or the diseases that HCV has been associated with. These include human subjects, non-
human primates, genetically engineered mice, as well as both human- and animal-derived
cells. The types of research questions that are being investigated using one or more of these
model systems include: (i) the mechanisms of infection, viral life cycle and persistence; (ii)
types, pathogenesis and mechanisms of HCV-associated liver diseases, including HCC; (iii)
the role of co-morbidity and environmental co-exposure factors; (iv) pharmacotherapy
options and treatment strategies; and (v) individual susceptibility factors. While there are a
number of animal models for the study of HCV infection and related liver diseases (see [10]
for a recent comprehensive review), few models have been applied to study the etiology and
mechanisms of liver cancer.
2. Mechanisms of HCV-associated liver carcinogenesis
Evidence exists to suggest that HCV may be both directly and indirectly involved in the
development and progression of HCC [5]. The evidence for the direct carcinogenic action of
HCV is less prominent than that for other carcinogenic viruses (e.g. papillomaviruses,
herpesviruses, Epstein-Barr virus) which integrate into cellular DNA and/or impair normal
controls of proliferation and cell death. HCV is a positive-strand RNA virus that replicates
outside of the nucleus and does not have any potential to integrate its genetic information
into the host cell's genome. HCV, however, has been found to be able to hijack a number of
normal molecular pathways that control cell cycle. Most attention has been devoted to the
interaction of various HCV non-structural proteins with cellular proteins that control
proliferation. For example NS5B has been shown to be bound in the cytoplasm to the
retinoblastoma (Rb) protein [11], the mechanism that is considered to be key in overcoming
infection-induced blocks to cell proliferation [12]. HCV proteins (core, NS3 and NS5A)
have also been suggested to disrupt the function of the tumor suppressor p53, which may be
a synergistic effect to the loss of Rb, but this interaction is not well understood (reviewed in
[13]). In addition, [14] revealed that the viral protein NS4B activates the expression of
several members of the PKC superfamily, stimulates the ERK/JNK signaling cascades, and
represses SOCS3 expression, resulting in the activation of STAT3 by enhancing its
phosphorylation. Activated STAT3 then stimulates MMP-2 and Bcl-2 expression, thereby
resulting in deregulation of cell transformation and apoptosis.
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These and other associated downstream events, such as DNA damage and mutations
resulting from inefficient cell cycle/apoptosis control, could lead to oncogenic
transformation of the affected cells which ultimately may develop into tumors. While similar
mechanisms may be part of indirect events leading to HCC (see below), the fact that
therapeutically-induced sustained antiviral response in patients with HCV leads to several-
fold reduction in the risk of HCC [15; 16] is indicative of the prominent role that the virus
plays in liver carcinogenesis. An over-arching issue with all of these cell culture studies,
however, is that the expression levels of viral proteins are often much higher than that which
occurs in the liver of infected persons. Studies in which individual viral proteins are
ectopically expressed must also be viewed with caution, as the trafficking and cellular
localization of these proteins may be quite different than in the infected hepatocyte.
The indirect mechanisms of carcinogenesis in the HCV-infected liver are thought to result
from the loss of virus-bearing hepatocytes which may lead to the increased rates of
proliferation. In addition, chronic inflammation and oxidative stress, coupled with increased
proliferation, may result in accumulation of mutations and oncogenic transformation of
hepatocytes (reviewed in [13]). The indirect mechanisms of carcinogenesis also seem likely
as a relatively small percentage of hepatocytes are HCV-infected in chronic carriers of the
virus [17; 18].
3. Human genome-wide association studies (GWAS)
Current human research in HCV field is primarily focused on understanding liver disease
susceptibility and progression and development of new treatments and patient management
strategies. There are major differences in how people respond to HCV infection and its
treatment. In addition to the virus serotype-specific reasons, host-specific factors play a clear
role in whether HCV will lead to chronic infection, as about 30% of persons who acquire
HCV infection resolve viremia, leaving only the antibody response as a marker of prior
exposure [19]. In addition, approximately 50% of the infected subjects do not respond to
interferon-based therapies [20; 21]. At least 5 recent independent candidate-gene and
genome-wide studies provide overwhelming evidence for the role of single nucleotide
polymorphisms in and near the interleukin (IL) 28B gene in the pathogenesis of HCV
infection (reviewed in [19]); however, few mechanistic clues exist to answer why IL-28B is
associated with spontaneous and treatment-associated resolution of HCV infection. A
number of other innate immunity genes have been also implicated, as the persons possessing
particular human leukocyte antigen types are more likely to recover from HCV [22] and
polymorphisms in genes encoding cytokines and other immunologic mediators also seem to
explain some HCV recovery [23; 24; 25].
In the GWAS of HCV-related HCC [26] the 5′ flanking region of MICA, the MHC class I
polypeptide-related sequence A gene on chromosome 6p21.33, was identified as
susceptibility locus and confirmed in an independent cohort. Albeit the locus conferred a
relatively small excess risk (odds ratio = 1.39), the finding is biologically plausible as the
level of soluble MICA protein, supposedly possessing anti-tumor activity through NK cells
and CD8-positive T-cells, was lower in individuals harboring the risk allele. Interestingly,
the authors found that the association of the risk allele was observed in the comparison
between CHC and HCC patients, but not in the comparison between CHC patients and
HCV-negative controls, suggesting that the genetic variants are associated with progression
from CHC to HCC rather than with the susceptibility to HCV infection. While potentially
interesting, it was suggested that the risk allele in the MICA gene is actually responsible for
increased progression of liver cirrhosis, which eventually contributes to development of
HCC, because the study by Kumar et al. [26] did not use HCV-related cirrhosis without
HCC as the controls [27]. A second GWAS of HCV-related HCC [28] was also conducted
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in Japan and identified a different gene, DEPDC5 (DEP domain containing 5) on
chromosome 22, as associated with HCC risk and confirmed the association using an
independent case-control population. Even though this study was slightly smaller in its
patient cohort size, the odds ratio for the top locus was also modest at 1.75. Questions
remain whether the susceptibility loci within MICA and DEPDC5 are associated with HCV-
related HCC in other ethnic groups, as both published studies were conducted in Japanese
cohorts. A small-scale study of recurrence-free survival in Japanese HCV-infected subjects
who underwent curative liver resection showed that polymorphisms in MICA or DEPDC5
do not correlate with HCC recurrence [29]. The authors did find that subjects with DEPDC5
minor allele have high susceptibility for HCC development, even if the fibrosis stage was
low. Thus, additional studies on other populations, with stratification based on viral sub-
genotypes and degree of cirrhosis should provide more comprehensive information on the
genetic etiology and heterogeneity of HCV-related HCC.
4. Non-human primates
Chimpanzees are the most relevant animal model for studies of HCV infection and related
immune and other effects [30]. They are considered a “complete” model with replication,
infection and virus production steps of the viral cycle. While the viremia levels are generally
high and the human-like host response comprises both innate and adaptive immunity, the
pathogenicity of HCV is relatively low in chimpanzees, making them a poor model for
chronic liver disease and HCV-associated HCC [10]. Only a few HCV-related liver cancers
have been reported in chimpanzees [31]. Moreover, virtually all use of chimpanzees in
biomedical research is being suspended starting in 2013, following a report by the Institute
of Medicine and a recommendation by a National Institutes of Health advisory panel. While
a possible exception is considered for the development of HCV vaccines, this model system
is increasingly difficult to access, and other non-human primates (e.g. the cynomolgus,
green and Japanese monkeys, the tamarins and baboons) are non-permissive species for
HCV infection [32].
5. Mouse models
The restricted host range of HCV has hampered the development of a suitable small animal
model of HCV infection; however, a number of research strategies have been proposed to
take advantage of the genetic engineering tools available in the mouse [10]. Of many mouse
models that have been developed in the past decade, only HCV transgenic mouse strains
have been employed in chronic studies designed to detect liver cancer as an endpoint.
5.1. Chimeric mouse models
A number of human liver chimeric mice were developed and are used as a model for HCV
infection and treatment [33]. The original strategy was to use T- and B-cell deficient mice
(termed SCID for severe combined immunodeficiency) that would tolerate human
hepatocyte (or hepatic progenitor cell) grafts into the liver [34]. This model is known as the
uPA model as it required, in addition to SCID phenotype, a plasminogen activator transgene
(Alb-uPA) which resulted in a loss of murine hepatocytes. Homozygosity of Alb-uPA was
associated with significantly higher levels of human hepatocyte engraftment in SCID mice
[34]. These mice could be infected with human HCV viruses (via serum) of various
genotypes and developed prolonged HCV infections with high viral titers after inoculation.
HCV viral proteins were shown to be localized to human hepatocyte nodules, and infection
was transferrable through three generations of mice confirming both synthesis and release of
infectious viral particles. While this model, in many ways, was revolutionary, its limitations
included excessive mortality, low breeding efficiency (since partially resolved by changing
the genetic background), transgene reversion, and challenges of colony management due to
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frail immune state of the mice. While these mice can sustain long-term infection and are
replicating the virus in a way similar to that of the human and chimpanzee liver [35], the
immunodeficiency of this model system prevents studies of adaptive immune response to
HCV infection. Importantly, there is no disease in these animals.
Another mouse model was developed to further increase the amount of grafting of human
cells into mouse liver. The so-called FRG model [36; 37] is mice lacking fumaryl
acetoacetate hydrolase, recombination activating gene 2, and the γ-chain of the receptor for
IL-2. Up to 95% of human hepatocyte chimerism can be achieved in these animals, human
HCV is effectively propagated, and the HCV-infected mice are responsive to antiviral
treatment [36]. While productive HCV infection could be seen in these mice, similar to uPa
mice, the lack of a functioning human immune system also precludes studies on immuno-
pathogenesis which plays a central role in progressive disease in chronically infected
individuals.
The most recent advancement in the chimeric mice for HCV research comes from the
development of the mouse with human immune system and liver cells, a model with great
promise to improve our understanding of HCV pathogenesis and treatment [38; 39]. To
induce murine liver cell death, a fusion protein of the FK506 binding protein (FKBP) and
caspase 8 under control of the albumin promoter (AFC8) was expressed in Balb/C Rag2/ C-
null mice. Next, human CD34+ human hematopoietic stem cells and hepatocyte progenitors
were co-transplanted which resulted in efficient engraftment of human leukocytes and
hepatocytes. These mice not only supported HCV infection in the liver and generated a
human immune T-cell response against HCV, but also developed pronounced human-like
molecular and histopathological signatures of liver hepatitis and fibrosis. While the initial
experiments showed relatively low levels of (~15%) human hepatocyte engraftment and
(possibly related) an absence of detectable HCV viremia, further improvements to this
model are underway (Su, L., personal communication).
5.2. Transgenic mouse models
Studies in transgenic mouse models, in which various HCV proteins are stably expressed,
indicate that HCV protein expression can be directly pathogenic and oncogenic [40; 41].
Although these model animals have a functional immune response which enables
immunogenicity studies, the transgene is typically sensed as ‘self’ and does not engender an
immune response. The transgenic animals also generally lack regulatory segments of the
HCV genome and thus do not support replication of virus, even if all the viral proteins are
expressed.
Several mouse models expressing HCV structural proteins (core, E1, E2 and p7) or
nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and NS5B), individually or in
various combinations, are available [42; 43]. In these mice, proteins are constitutively
expressed in all liver parenchymal cells owing to the control by liver-specific promoters.
Most of the HCV transgenic mouse strains do not exhibit overt liver disease, especially in
the first 12 months of life, despite high expression levels of HCV proteins. The earliest
pathological liver phenotype that has been reported appears to be moderate to severe
steatosis which develops between 3 and 10 months of age [40; 41; 44], and is a common
feature in humans with chronic HCV infection. Evidence for a spontaneous increase in
oxidative stress in ageing HCV transgenic mice is limited [45], and is not accompanied by
either inflammation or necrosis [46]. While hepatic tumors have been observed in some of
these models [40; 41; 47; 48; 49] the incidence varies widely. Liver tumors develop only in
the mice of advanced (>13 months) age and largely without much adverse liver pathology,
except for steatosis. A number of studies have used HCV transgenic mouse models for
studies of co-carcinogenesis or co-morbidity (see below).
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A model of transient transfection with HCV proteins-containing plasmids has been also
proposed [50; 51]. This model exploits the technique of hydrodynamic tail vein injection of
naked plasmid DNA, a simple and effective in vivo gene delivery method into hepatocytes
[52]. Transient hepatic transgene expression of the HCV nonstructural 3/4A protein was
demonstrated by Ahlen et al [50] and it was estimated that 10-30% of liver cells expressed
the transgene as early as 24 hrs post-infection. The advantages of this model are its
flexibility with regards to the researcher's ability to transfect various parts of the HCV
genome and the fact that not every cell is transfected, mimicking the human condition. The
transient (i.e. short-term) nature of the transfection, however, precludes the use of this model
in chronic and carcinogenesis studies.
6. In vitro models
6.1. Primary human hepatocytes
Among many in vitro models that have been used in HCV research, adult primary human
hepatocytes are considered to be the most human-relevant cell-based liver model [53]. It has
been demonstrated more than a decade ago that human serum-derived HCV may infect these
cells in culture [54]. Primary adult human hepatocytes are permissive to viral genome
replication, although the level of replication is typically very restricted in magnitude [55;
56]. Primary adult human hepatocytes are closest to the in vivo situation with respect to
production of more authentic, lipid-associated HCV particles [57]. Importantly, this model
system has been shown to induce an early innate antiviral response upon HCV infection [53]
and be responsive to inhibition of HCV by interferon [58; 59]. In fact, the interferon
response and innate immune response, even though desired features of this model, limit the
spread of HCV infection [60; 61]. These cells are of limited access, difficult to handle, and
support HCV replication only inefficiently [60], which makes them not widely used. Despite
these limitations, potential relevance of this model to studies of HCV-induced liver disease
is considerable.
A recent report by Bose et al [62] suggested that HCV virus may induce
epithelialmesenchymal transition in primary human hepatocytes. This study showed that cell
culture-grown HCV leads to a transformation of primary hepatocyte cultures into fibroblast-
like cells, which may explain the origins of the fibrotic response in human HCV-infected
patients. The same group has shown previously that HCV infection of primary human
hepatocytes may result in immortalization [63]. While intriguing, these findings need
independent confirmation and a better understanding of the hepatocyte transition states from
liver-like morphology to fibroblast or immortalized phenotype.
6.2. Liver-derived cells
One of the most widely used in vitro models for studies of HCV is the Huh7 cell line and its
closely related variants. Very efficient replication of HCV can be achieved in these cells,
possibly because of a high basal expression level of the liver-specific microRNA, miR-122.
The binding of miR-122 to its target sequences in the HCV genome does not inhibit the
function of the viral RNA but instead positively regulates its replication [64]. Fukuhara et al
[65] showed that endogenous expression levels of miR-122 differ widely among hepatic and
nonhepatic cells. In fact, it was observed that miR-122 expression was more than 2 orders of
magnitude higher in Huh7 cells than that in HepG2 or Hep3B cells. Expression in non-liver
derived cells (NCI-H-2030, SK-OV3, SW620, RERF-LC-AI, Caki-2, MC-IXC, 293T,
Hec1B, 769-P, A-427, SW780, and SK-PN-DW) was even lower. Expression of miR-122 in
HepG2 cells permitted efficient HCV RNA replication and infectious virion production.
When a missing HCV receptor is also expressed, these cells support viral entry and the
entire HCV life cycle [66]. Although Huh7 cells represent somewhat of a gold standard for
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permissiveness for HCV replication, they express a mutant p53 gene that is transcriptionally
inactive and are thus not suitable for many studies related to HCV-associated
carcinogenesis.
Several studies have suggested that Hep3B cells can also support levels of HCV replication
and virus particle production, similar to that found in Huh7-derived cells, with no selection
or adaptation [67]. In addition, interferon-stimulated gene expression is significantly and
differentially up-regulated in Hep3B cells following viral infection [68]. However, others
have reported that while the early events in HCV infection are efficient in Hep3B cells, later
steps of the viral life cycle such as steady-state replication, de novo virus production and/or
spread are impaired compared to Huh7 cell cultures [68]. This diminished response was
attributed, at least in part, to HCV-induced innate signaling, similar to that in primary human
hepatocytes.
Huh7 and other traditional cell-based models are used in conjunction with cell-culture
adapted viruses and thus may not completely mimic the events that occur during a natural
HCV infection in vivo [69]. Recently, HepaRG cells that are capable of differentiating into
hepatocytes and biliary epithelial cells, were shown to be susceptible to in vitro infection
with human serum-derived HCV and able to support long-term production of infectious
lipoprotein-associated enveloped HCV particles [70]. This study also demonstrated the
potential for HepaRG cells to be used as a surrogate infection system for the screening of
viral entry inhibitors.
The in vitro models of HCV infection are also invaluable for translational clinical research.
For example, while HCV infection treatment with interferon alfa (IFN-α) alters cellular
response pathways of innate immunity to suppress HCV infection in many subjects, the
response to such therapy is not uniform. Lau et al [71] modeled the relationship between
chronic HCV replication, levels of IFN and the clinical observation of interferon-stimulated
tolerance in hepatocytes. The authors demonstrate that when Huh7 cells were incubated with
low levels IFN-α-2a, expression of interferon-stimulated genes was associated with an
increase in level of HCV RNA indicating that constitutive exposure to IFN may induce
some degree of interferon tolerance. This has also been described in the mouse liver [72].
6.3. Extrahepatic cells
miR-122 has been shown to enable replication of stable HCV RNA replicons in many non-
liver cells, including human embryonic kidney epithelial (HEK-293) cells [73]. In other cell
lines, such as wild-type murine fibroblasts that are restricted for HCV RNA replication,
deletion of interferon regulatory factors and expression of liver-specific miR-122 is
necessary to facilitate the synthesis of HCV replicons [74]. Still, while exogenous
expression of miR-122 in non-hepatic cells facilitates efficient viral replication, production
of infectious particles is lacking in such cells, possibly due to inefficient lipid metabolism.
Indeed, HCV assembly is known to occur on the surface of lipid droplets, a process that is
facilitated by the interaction of lipid droplet-associated protein TIP47 which binds to RNA-
loaded NS5A [75]. Liver-specific mechanisms for very-low density lipoprotein secretion
also appear to be involved in HCV release from hepatocytes, and likely contribute to the
hepato-tropism of the virus [76].
6.4. Stem cell-derived liver-like cells
The field of in vitro liver research has been recently enriched by the introduction of stem
cell-derived liver-like cells. Recent studies show that both embryonic [77], and induced
pluripotent [78] stem cells can be differentiated into hepatocytes that are phenotypically
similar to human fetal liver. These models begin to be applied for studies of HCV. A human
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iPS-derived hepatocyte-like cell-based model [79] offers the possibility to study genetic
defects that impact HCV infection. This study reported that induced human liver-like cells
expressed known HCV host factors involved in HCV entry and supported the entire life
cycle of genotype 2a HCV reporter virus, and that incubation with antiviral drugs caused a
significant decrease of viral production. Cell culture supernatants from this model were able
to infect HuH-7.5 cells, and HCV infection induced an antiviral inflammatory response
similar to that induced in hepatocytes during chronic liver disease. Furthermore, secretion of
TNF-α, and IL-28B/IL-29 was detected in cell culture supernatants. Therefore, as suggested
by the authors, we can speculate that iPSCs generated from patients with a genetic
background that impacts HCV infection could serve as a model for studying the influence of
innate immunity on such infection, which could enhance our current understanding of
interferon-based therapy.
7. Use of mouse model systems to understand factors that facilitate cancer
development in HCV-infected liver
Spontaneous development of liver tumors have been observed only in a couple of HCV
transgenic mouse strains, usually between 13 and 24 months of age [40; 41; 42]. Most of the
HCV transgenic mouse models exhibit a limited overt liver phenotype, even late in life [42],
yet are susceptible to a number of additional hepatotoxic challenges such as iron overload
[80], carbon tetrachloride [81], alcohol [49], acetaminophen [82], or aflatoxin B1 [83].
Studies in HCV transgenic mice have demonstrated that expression of various HCV proteins
may enhance susceptibility to other carcinogens. With regards to studies of comorbidity,
iron overload [80], hepatitis B virus X protein [84], or intestinal colonization with H.
hepaticus [85] have been shown to promote liver cancer in HCV-transgenic mice. With
regards to studies of dietary factors, alcohol [49] and aflatoxin B1 [83] promoted the
development of HCC in HCV transgenic mouse strains that normally do not develop cancer.
These studies not only establish a model for studies of the mechanisms of co-carcinogenesis
of HCV and other factors, but it also indicates a crucial role for direct viral protein effects in
the synergy between these factors. Furthermore, these findings are particularly interesting
because both alcohol ingestion and exposure to aflatoxin B1 are known to increase the risk
of HCC in patients with chronic hepatitis C.
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